Laura G. Hansen
Investor Relations Contact chez DENALI THERAPEUTICS INC.
Profil
Laura G.
Hansen is currently the Vice President-Investor Relations at Denali Therapeutics, Inc. She previously worked as the Director-Corporate Communications at Corvas International, Inc. from 2001 to 2002, Director-Corporate Communications at FibroGen, Inc. from 2002 to 2012, Senior Director-Corporate Communications at Threshold Pharmaceuticals, Inc. from 2012 to 2016, and Vice President-Investor Relations at Aimmune Therapeutics, Inc. from 2016 to 2019.
She also worked as the Vice President-Corporate Affairs at BlackThorn Therapeutics, Inc. from 2019 to 2020.
Dr. Hansen received her undergraduate and doctorate degrees from The University of Texas at Austin.
Postes actifs de Laura G. Hansen
| Sociétés | Poste | Début |
|---|---|---|
| DENALI THERAPEUTICS INC. | Investor Relations Contact | - |
Anciens postes connus de Laura G. Hansen
| Sociétés | Poste | Fin |
|---|---|---|
BlackThorn Therapeutics, Inc.
 BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/09/2020 |
| AIMMUNE THERAPEUTICS, INC. | Investor Relations Contact | 01/03/2019 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Investor Relations Contact | 01/02/2016 |
| FIBROGEN, INC. | Public Communications Contact | 01/07/2012 |
| Corvas International, Inc. | Public Communications Contact | 01/07/2002 |
Formation de Laura G. Hansen
| The University of Texas at Austin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| DENALI THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Corvas International, Inc. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
BlackThorn Therapeutics, Inc.
BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA. | Health Technology |
